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Abstract (150 words maximum) 
Numerous pharmacogenetic clinical guidelines and recommendations have been published, but 
barriers have hindered the clinical implementation of pharmacogenetics. The Translational 
Pharmacogenetics Program (TPP) of the NIH Pharmacogenomics Research Network was established in 
2011 to catalog and contribute to the development of pharmacogenetic implementations at eight US 
healthcare systems, with the goal to disseminate real-world solutions for the barriers to clinical 
pharmacogenetic implementation. The TPP collected and normalized pharmacogenetic implementation 
metrics through June 2015, including gene-drug pairs implemented, interpretations of alleles and 
diplotypes, numbers of tests performed and actionable results, and workflow diagrams. TPP participant 
institutions developed diverse solutions to overcome many barriers, but the use of Clinical 
Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the 
institutions. The TPP also collected some pharmacogenetic implementation outcomes (scientific, 
educational, financial, and informatics), which may inform healthcare systems seeking to implement 
their own pharmacogenetic testing programs.  
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
Introduction 
Patients’ risk for adverse drug effects or therapeutic failure might be decreased by personalizing 
pharmacotherapy for select drugs to each individual’s genetics. Indeed, the United States Food & Drug 
Administration (US FDA) lists over 160 drugs with “Pharmacogenomic Biomarkers in Drug Labeling,”(1) 
in which many drugs include recommendations for adjustment of therapy based on patients’ genetics. 
Moreover, the Clinical Pharmacogenetics Implementation Consortium (CPIC) has published 
pharmacogenetic guidelines for 33 drugs as of mid-2016.(2) Despite the growing body of knowledge of 
gene–drug interactions and their clinical significance, the clinical implementation of pharmacogenetics 
has been slow. A recent nationwide survey found that only 10% of physicians felt adequately informed 
about pharmacogenetic testing, and only 13% had ordered a pharmacogenetic test within the past 6 
months.(3) The slow clinical implementation of pharmacogenetics is due to several recognized 
barriers,(4, 5) including (i) logistics of performing accurate and rapid turnaround genotyping in a Clinical 
Laboratory Improvement Amendments (CLIA)-approved laboratory setting; (ii) lack of infrastructure or a 
standardized format for the return of pharmacogenetic test results in the electronic health record (EHR); 
(iii) lack of infrastructure or standardized format for pharmacogenetic clinical decision support (CDS) in 
the EHR; (iv) lack of prospective genotype-directed randomized clinical trials validating 
pharmacogenetic-guided approaches; (v) inexperience of clinicians in interpreting and acting on 
pharmacogenetic information; (vi) paucity of clear and consistent recommendations for 
pharmacogenetic testing by professional associations; and (vii) cost and reimbursement considerations 
related to pharmacogenetic testing. 
The Translational Pharmacogenetics Program (TPP) of the NIH Pharmacogenomics Research 
Network (PGRN) was established in 2011 as an implementation science project to study and contribute 
to the development of pharmacogenetic implementations at eight US healthcare systems. The overall 
goals of the TPP were to harness the multidisciplinary expertise and extensive institutional investments 
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at each participating site, implement routine pharmacogenetic-based dosing and drug selection within 
diverse healthcare systems, identify common approaches to implementation, identify and propose 
solutions to logistic barriers to implementation, and disseminate ‘best-practice’ guidelines for 
overcoming those barriers.(4) The TPP included eight healthcare systems affiliated with the following 
institutions: Harvard University, Mayo Clinic, Ohio State University, St. Jude Children’s Research 
Hospital, University of Chicago, University of Florida, University of Maryland, and Vanderbilt University. 
In this manuscript, we report the experience from seven TPP sites through June 2015 on 
pharmacogenetic implementation metrics, areas of diversity in pharmacogenetic implementations, and 
areas of similarity in pharmacogenetic implementations. (Harvard University chose to explore next 
generation sequencing approaches and had not yet implemented pharmacogenetic testing at the time 
of data collection). We also report on selective scientific, educational, financial, and informatics 
outcomes at some of the TPP sites. We believe that the metrics and outcomes of these initial 
pharmacogenetic implementations across the TPP demonstrate the first steps and approaches for 
overcoming the aforementioned barriers to pharmacogenetic clinical implementation, which will be 
useful for other health care systems considering clinical implementation of pharmacogenetics.    
 
Results 
Implementation metrics 
A major coordinated task of the TPP was to summarize metrics that described each of the 
pharmacogenetic implementations across seven TPP sites. A summary of the major metrics of the 
pharmacogenetic implementations through June 2015 is presented in Table 1 (n = 20,258 total patients 
tested), and areas of similarity and diversity are discussed in the following sections. The numbers of 
distinct test results, total numbers of results reported to EHRs, and the numbers of actionable 
genotypes for select gene-drug pairs implemented through June 2015 are displayed in Table 2. 
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Actionable results were defined by CPIC guidelines for all gene-drug pairs, except for CYP2C9/VKORC1 
where actionable was defined by the FDA label when the expected warfarin dose did not include the 
standard 5mg starting dose, and the individual sites defined their own actionable CYP2D6-codeine 
results. While all of the results could inform decisions about drug therapy, nearly 1 out of 4 (23.6%) of 
the pharmacogenetic tests (n = 22,928 total) were classified as potentially actionable since the 
associated CPIC recommendation included a change of drug or dose. 
For the three most commonly implemented gene-drug pairs (CYP2C19-clopidogrel, TPMT-
thiopurines, and SLCO1B1-simvastatin; Table 3), additional detailed metrics from each TPP site were 
collected and normalized into tables that were made publicly accessible via the Pharmacogenomics 
Knowledgebase website (PharmGKB®)(6) (https://www.pharmgkb.org/page/tppTables) and also 
available online as supplementary material (online supplemental files 1, 2, and 3). These tables report 
the specific genotyping platforms used, haplotypes tested and their functional interpretations, diplotype 
and phenotype counts, modes of pre-test and post-test CDS, and clinical recommendations based on the 
test results. For the most commonly implemented gene-drug pair (CYP2C19-clopidogrel), workflow 
diagrams illustrating the clinical processes and flow of data related to the pharmacogenetic 
implementations were also created by some of the sites and made publicly available 
(https://www.pharmgkb.org/page/tppTables) and online as supplementary material (online 
supplemental file 4).  
 
Areas of diversity 
The pharmacogenetic implementation metrics revealed that the TPP sites were diverse in nearly 
every area of their pharmacogenetic implementations (Table 1). Two sites implemented 
pharmacogenetic testing as part of clinical research protocols, two sites implemented as part of clinical 
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practice, and three sites implemented pharmacogenetic testing via both clinical research protocols and 
clinical practice. The clinical research implementations performed pharmacogenetic testing for patients 
that were recruited and consented for IRB-approved clinical research studies, whereas the clinical 
practice implementations added pharmacogenetic testing in certain clinical settings to guide drug 
therapy decisions. A surprising area of diversity was the roles of those directly involved in the 
pharmacogenetic testing workflow for CYP2C19-clopidogrel (online supplemental file 4). For example, 
pharmacists had direct roles in the patient interface at the University of Florida(7) and St. Jude 
Children’s Hospital(8), but pharmacists were selectively involved in specific drug-gene interactions at 
Vanderbilt University.(9) Pharmacists were not involved in the patient interface at Ohio State 
University(10) or the University of Maryland,(11) but they were involved in the pharmacogenetic 
implementation design and evaluation. Ohio State University was unique in that genetic counselors 
directly interacted with patients in the pharmacogenetic workflow.(12)  
The use of reactive testing (i.e., pharmacogenetic test only ordered in response to a specific 
trigger, such as a drug order) versus preemptive testing (i.e., pharmacogenetic test ordered for all 
patients presenting to the healthcare system or a select clinical setting without a specific trigger) also 
varied between sites. At Vanderbilt University, the CYP2C19-clopidogrel test was ordered if the patient 
was scheduled for a left heart catheterization. At the University of Maryland, the CYP2C19-clopidogrel 
test was ordered if the patient consented to participate in a research study and was admitted to the 
cardiac catheterization laboratory for a left heart catheterization. The CYP2C19-clopidogrel test was 
reactively ordered at the University of Florida if the patient received percutaneous coronary 
intervention. Under their research protocol, St. Jude Children’s Hospital preemptively tested all new 
consenting patients for CYP2C19, the University of Chicago preemptively tested adult patients receiving 
outpatient care in Department of Medicine clinics, and Vanderbilt University also preemptively tested 
adult outpatients in Primary Care, Cardiology, and Endocrinology. At Mayo Clinic, testing was not 
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recommended in response to an order for clopidogrel, but if the results for CYP2C19 were already 
available (from a previous test/indication) they were used to guide clopidogrel therapy. At Ohio State 
University, the CYP2C19-clopidogrel test was ordered for any patient with hypertension or heart failure 
that consented to be part of a research study evaluating the impact of genomic counseling.(10)  
Across the TPP, pharmacogenetic testing was implemented within numerous clinical settings 
(e.g., inpatient and outpatient, general medicine and sub-specialties, etc.) and target patient 
populations (e.g., adults and children, drug-specific, disease-specific, high-risk ethnic groups, etc.). 
Several different genotyping platforms were used across the TPP sites, which had high call rates (>99%) 
and a range of turn-around-times (e.g., the median turn-around-time for reactive testing was 2.6 days 
with a range of 0.3 - 16 days). 
 
Areas of similarity 
Despite significant diversity of pharmacogenetic implementations, a common theme of 
successful implementation across sites was the leadership of clinician-champions, use of 
multidisciplinary teams, and strong institutional involvement, including the infrastructure and resources 
to execute. TPP programs were also similar in the clinical recommendations offered during prescribing. 
Much of this parity between programs can be attributed to the common use of CPIC guidelines. Other 
similarities in luded the specific pharmacogenetic tests (gene-drug pairs) implemented (Table 2) and the 
general process for result interpretation. The more detailed tables for CYP2C19-clopidogrel, TPMT-
thiopurines, and SLCO1B1-simvastatin (available as online supplemental files 1, 2, and 3 or at 
https://www.pharmgkb.org/page/tppTables) showed general uniformity of the process for test result 
interpretation. Interpretation was consistent with the stepwise process advised by CPIC guidelines 
(patient diplotype is translated into a predicted phenotype, which is linked to a clinical 
recommendation), and the recommendations themselves were mostly consistent with those given in 
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CPIC guidelines. For example, in line with the strong recommendation for alternative therapy in CYP2C19 
poor metabolizers, six out of seven sites recommended or considered an alternative drug instead of 
clopidogrel. Only one site, Ohio State University, did not make specific drug treatment 
recommendations (instead, the report only included the diplotype, predicted phenotype, and several 
informative citations, without an explicit recommendation). In line with the moderate CPIC classification 
for recommending alternative therapy in CYP2C19 intermediate metabolizers, five out of seven sites 
recommended an alternative drug to clopidogrel in CYP2C19 intermediate metabolizers; however, the 
University of Maryland also recommended that the dose of clopidogrel could be increased, and Ohio 
State University (like in the case of poor metabolizers) did not give an explicit recommendation. In about 
half of cases, therapy was changed for patients with actionable genotypes (Table 1; median change rate 
= 48% and range = 36% - 100%).  When an actionable genotype result was detected and the therapy was 
not changed, prescribers stated several justifications (e.g., contraindication to the alternative therapy, 
increased cost of the alternative therapy, patient preference, and continuation of therapy managed by 
another prescriber).(13, 14)   
 
Scientific outcomes 
The TPP catalyzed a wealth of data and infrastructure to facilitate research. For example, at Ohio 
State University, the patients who participated in pharmacogenetic implementation studies(10, 12) also 
consented to participate in follow-up survey research and retrospective chart reviews using the data in 
their EHRs. Those opportunities spurred several ongoing “spin-off” research projects. The University of 
Chicago studies pharmacogenomic implementation and clinical decision support via the “1,200 Patients 
Project”.(15-18) Three TPP sites, the University of Florida, University of Maryland, and Vanderbilt 
University, are funded as part of the NIH’s “Implementing GeNomics In pracTicE” (IGNITE) Network,(19) 
which includes a pharmacogenetics interest group that is undertaking numerous multi-institution 
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projects. Mayo Clinic and Vanderbilt University are also funded as part of eMERGE,(20) which had a 
pharmacogenetics-focused project and other research efforts to learn from the pharmacogenetic 
implementations and the large population of genotyped patients. Several TPP groups, joined by several 
other institutions as part of the IGNITE Pharmacogenetics Interest Group, have conducted multi-
institution analyses of cardiovascular outcomes following clinical implementation of CYP2C19-genotyped 
guided antiplatelet therapy. The data resulting from this collaborative effort will help to define the 
impact of pharmacogenetics on clinical outcomes in cardiovascular patients undergoing percutaneous 
coronary intervention. In addition, Mayo Clinic is leading the ongoing international, multi-center, 
randomized, prospective clinical trial TAILOR PCI to assess whether CYP2C19-genetically tailored anti-
platelet therapy can improve clinical outcomes with clopidogrel after percutaneous coronary 
intervention with stent implantation (ClinicalTrials.gov identifier: NCT01742117).(21)  
 
Educational outcomes 
The TPP sites individually created and continue to update numerous pharmacogenetic 
educational materials for patients, clinicians, and researchers that are freely available online.(22-30)  A 
collection of links to resources can be found on PharmGKB® at 
https://www.pharmgkb.org/page/pgxImplementationResources.  These resources provide a wealth of 
pharmacogenetic information that includes pharmacogenetic publications, presentations, videos, 
competencies, residency programs, conferences, continuing education, and core laboratory services for 
genetic testing. Though not funded as part of TPP, the University of Florida publishes a newsletter 
geared toward personalized medicine, particularly pharmacogenetics, titled “SNP•its” 
(http://personalizedmedicine.ufhealth.org/tag/snpits/), which evaluates and summarizes journal articles 
that are most readily applicable and relevant to practicing clinicians. Information on this publication as 
well as educational and implementation materials are available on their website 
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(http://personalizedmedicine.ufhealth.org/).(26) The Mayo Clinic created a variety of educational 
materials for providers and patients to enhance pharmacogenetic implementation into practice. These 
include online resources linked to CDS to be used by providers at the point-of-care (“AskMayoExpert” 
enterprise knowledge content management), grand rounds presentations, online modules and videos, 
and brochures, as well as links to pharmacogenetic results in the patient portal 
(http://mayoresearch.mayo.edu/center-for-individualized-medicine/drug-gene-testing.asp). St. Jude 
Children’s Research Hospital has created a website (www.stjude.org/pg4kds/implement) to track which 
genes/drugs it has implemented and contains implementation specific publications, presentations, as 
well as gene-specific clinician pharmacogenetic competencies. Vanderbilt University developed “My 
Drug Genome,” (www.mydruggenome.org)(22) which is a resource to learn about how genetics can 
affect the way medications work and how genetic results can be incorporated into personalized patient 
care. Additionally, Vanderbilt has led the creation of a site to organize clinical decision support 
information across multiple sites.(28)  Vanderbilt also supported the development of a Coursera MOOC 
(Massive Open Online Course) in personalized medicine that includes multiple pharmacogenetic 
modules.(29)   
St Jude Children’s Research Hospital and University of Florida established the first two American 
Society for Health System Pharmacists-accredited post-graduate year 2 pharmacy residencies in clinical 
pharmacogenomics. The University of Chicago,(16) Ohio State University,(31) Mayo Clinic, and 
Vanderbilt University offer post-doctoral fellowship programs that are accredited by the American Board 
of Clinical Pharmacology and offer training in pharmacogenomics. Additionally, students enrolled in the 
pharmacy and medical schools at the University of Florida and University of Maryland, respectively, 
received their personal pharmacogenetic genotype test results as part of their curriculum.(32, 33) TPP 
members continue to present at grand rounds, in-services, and high profile domestic and international 
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symposia, which have been shown to significantly improve attitudes toward pharmacogenetic 
testing(34) and pharmacogenetic testing rates.(7)  
 
Financial outcomes 
Cost and reimbursement for pharmacogenetic testing remained a highly complex issue. 
Methods for estimating cost and payment methods for pharmacogenetic testing differed between, and 
even within, the TPP sites. Therefore direct comparisons of costs between TPP sites were not possible. 
Payment for clinical pharmacogenetic testing after submission to third party payers was sometimes sent 
to the patient themselves or covered by the institution. The processes used for billing and the payer 
varied based on a patient’s inpatient or outpatient status at the time of the test. Payment for research 
protocol pharmacogenetic testing was typically covered by research grants. To further complicate this 
issue, the costs of genetic testing and reimbursement policies by third party payers are rapidly changing; 
the TPP provided a snapshot in time on these financial issues.  In the University of Florida’s 
pharmacogenetic testing program, seven different third party payers (including Medicare) reimbursed 
for the CYP2C19-clopidogrel test, with an 85% reimbursement rate during the first month of billing.(14)  
Additionally, the hospital at the University of Florida agreed to cover the costs of the test for inpatients 
as part of the diagnosis-related group based payment. A cost-effectiveness study by investigators at the 
University of Maryland found that CYP2C19 genotype-guided antiplatelet therapy selection may be 
more cost-effective and may provide more clinical value due to fewer adverse outcomes,(35) and 
additional cost-effectiveness data on CYP2C19 genotype-guided antiplatelet therapy are expected from 
the IGNITE Pharmacogenetics Interest Group. 
 
Informatics outcomes 
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 The TPP sites developed infrastructure to support the ordering of pharmacogenetic tests and 
the return of test results, which was designed to fit into each site’s workflow.  In general, the existing 
test order/result process within each EHR system could be leveraged, but several types of customization 
were necessary to enable the pharmacogenetic data to be used for CDS.  For example, currently there 
are no standards for representing genomic test results within EHR systems.  Those results can include 
collections of sequence data, genotypes, named alleles (e.g., star nomenclature), and phenotypic 
interpretations (e.g., metabolizer status), and each TPP site individually determined how those data 
would be represented and stored.  The storage location of pharmacogenetic results to be displayed in 
clinical systems also varied among sites.  In some cases pharmacogenetic data were stored directly 
within the EHR as a traditional lab test, in others the genomic data were stored in an ancillary system 
linked to the EHR, and in some it was a combination of both approaches. In all cases, some level of 
customization was needed in order to store and present the information. While some common 
challenges were identified, heterogeneity in data representation and storage location complicated the 
comparison of implementations among sites and, along with differences in clinical workflow, limited the 
portability of CDS rule algorithms. 
 
Discussion 
Many barriers to the clinical implementation of pharmacogenetics have been recognized,(4, 5) 
but the PGRN TPP, which collected metrics and outcomes from pharmacogenetic implementations at 
diverse US healthcare systems, demonstrated that some of those barriers can be overcome.   While the 
NIH PGRN TPP provided seed-funding for the programs described herein, some programs were active at 
the time TPP was initiated. In all cases, significant institutional resources were required to develop the 
programs that have been described.  Additionally, some of the groups have obtained significant 
additional extramural funding to advance their pharmacogenetic programs.  However the lessons 
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learned and barriers overcome at these sites can facilitate more cost effective implementations at other 
sites, if they take advantage of the resources developed and knowledge shared from the various TPP 
sites.   A variety of genotyping platforms were utilized in CLIA-approved laboratory settings (both on site 
and outsourced), demonstrating the availability of accurate genotyping methods in CLIA-approved 
laboratories. A variety of methods for ordering and returning pharmacogenetic test results and for CDS 
were utilized in EHRs, demonstrating the diversity of approaches to establishing the information 
infrastructure needed to provide CDS for pharmacogenetics. CPIC guidelines were widely used as the 
framework for pharmacogenetic test interpretation and clinical recommendations, demonstrating the 
importance of evidence-based, clinical pharmacogenetic guidelines in the implementation of clinical 
pharmacogenetic programs.  
Despite these successes in overcoming several barriers encountered by the TPP, some barriers 
still remain. For example, CPIC recently standardized the terms for phenotypes and for allele function 
used within CPIC guidelines to represent the interpretation of pharmacogenetic tests (e.g., metabolizer 
status)(36) and registered those terms within the Logical Observation Identifiers Names and Codes 
(LOINC) terminology (http://loinc.org/). However lack of accepted, standards-based methods for 
representing many elements of pharmacogenetic (and all genetic) test results persists.  Specifically, 
genomic data can be reported and stored in a variety of formats (e.g., diplotypes, variant call format 
[VCF], Human Genome Variation Society [HGVS] or star allele nomenclatures, positive/negative carrier 
status) that may be stored in the EHR as discrete data elements or as part of narrative text. This 
heterogeneity in data representation can be a significant barrier to the retrieval and exchange of 
pharmacogenetic data. Moreover, data on cost/reimbursement of pharmacogenetic testing and 
prescriber adherence to therapy recommendations were not able to be consistently collected and 
compared across TPP sites. 
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The pharmacogenetic implementation metrics of the TPP revealed promising potential for 
clinical relevance. The TPP demonstrated that it is possible to implement pharmacogenetic testing for 
several drugs, and many sites are implementing additional tests. Based on the large numbers of 
functionally annotated haplotypes in genes known to affect drug metabolism or transport, we expected 
to see a large amount of genetic variability in the patient populations, and the metrics of the TPP 
confirmed that expectation. Indeed, 354 distinct test results were observed when only 8 different gene-
drug pairs were considered. The TPP also demonstrated the potential for widespread pharmacogenetic 
implementation. Nearly 100,000 pharmacogenetic test results were posted in the respective EHRs at 
seven TPP healthcare systems thus far. The potential feasibility for widespread application was also 
demonstrated by the variety of patient populations and clinical settings in which pharmacogenetic 
testing was implemented. And finally, nearly 1 out of 4 pharmacogenetic tests had a potentially 
actionable result, which demonstrated the numerous potential opportunities to personalize patients’ 
pharmacotherapy to their genetics. 
The institutions that comprise the TPP have also provided valuable information for healthcare 
systems seeking to implement their own pharmacogenetic testing programs. This includes a variety of 
resources that are freely available online (e.g., publications, videos, continuing education, conferences, 
lookup tables, and workflow diagrams) (22-30) and the identification of areas of diversity and similarity 
among the TPP sites in this manuscript. Despite the diversity in methods of implementation, the clinical 
recommendations for drugs were largely the same across sites, showing that there are actionable 
recommendations for drugs that can be implemented with minimal ambiguity. Due to the diversity in 
clinical workflows across sites, it may be difficult to exactly replicate an implementation from one site 
directly to another, but this diversity provides the opportunity to study the strengths and limitations of 
each implementation from a process/workflow perspective. The diversity among the sites in the TPP 
indicated that healthcare systems can customize their pharmacogenetic implementations to their local 
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clinical workflows and specific needs (as with any clinical service), and the TPP demonstrated that 
multiple different pharmacogenetic implementation models can be achieved that are all based on the 
same clinical guideline. Moreover, CPIC maintains a list of institutions that have indicated they are 
implementing CPIC guidelines clinically that exemplify additional models of pharmacogenetic 
implementation (not just TPP sites).(37) The areas of similarity (the specific pharmacogenetic tests 
implemented, the general process for result interpretation, and the clinical recommendations) were 
facilitated by the utilization of the CPIC guidelines, and thus the CPIC guidelines represent a useful 
framework for other healthcare systems seeking to implement their own pharmacogenetic testing 
programs.  
In conclusion, through implementation science, the collection and normalization of 
pharmacogenetic implementation metrics across seven TPP sites revealed a large amount of diversity 
among pharmacogenetic implementations related to clinical context and workflow. However a common 
theme of successful implementation across sites was the leadership of clinician-champions and 
multidisciplinary teams, as well as the need for institutional investment, including the infrastructure and 
resources to execute. Moreover, the use of CPIC guidelines provided a common thread across sites. The 
TPP demonstrated that some of the barriers to the clinical implementation of pharmacogenetics can be 
overcome, but some barriers still remain. The TPP directly and indirectly catalyzed many 
accomplishments in multiple areas, including scientific, educational, financial, and informatics, which 
beckons a call for more support of programs like the TPP. The TPP showed that these accomplishments 
are possible, but more work needs to be done in identifying solutions to overcoming the remaining 
barriers to the clinical implementation of pharmacogenetics more broadly across diverse healthcare 
settings and patient populations. 
 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
Methods  
The design and goals of the TPP were previously described.(4) Briefly, each TPP site 
implemented one or more pharmacogenetic tests into clinical practice or clinical research protocols, and 
the sites have individually published their implementation profiles.(8, 10, 11, 14, 15, 38-44) TPP 
participants met in-person biannually and at least quarterly by teleconference. A Data Collection & 
Harmonization Working Group was created to facilitate the collection of normalized data, and the 
Working Group consisted of at least one representative from each TPP site that met via a weekly 
web/teleconference. Sites were surveyed on multiple planned metrics describing their individual 
implementations(4) and on the gene-drug pairs that either were implemented or planned to be 
implemented by 2015. Due to the small sample size (n = 7 TPP sites contributed metric data), only 
descriptive statistics were calculated using Microsoft Excel. The most commonly implemented gene-
drug pairs were chosen for additional types of data collection using standardized templates created in 
Microsoft Excel or PowerPoint. For the three most commonly implemented gene-drug pairs (CYP2C19-
clopidogrel, TPMT-thiopurines, and SLCO1B1-simvastatin), standardized tables reporting the specific 
genotyping platforms used, haplotypes tested and their functional interpretations, diplotype and 
phenotype counts, modes of pre-test and post-test CDS, and clinical recommendations based on test 
results were created in Microsoft Excel. For the most commonly implemented gene-drug pair (CYP2C19-
clopidogrel), workflow diagrams illustrating the clinical processes and flow of data related to the 
pharmacogenetic implementations were also created by some institutions. Some of the workflow 
diagrams utilized a common “swim lane” format that allowed for more direct comparison of workflows 
across TPP sites. Each “swim lane” represented a generalized role of an actor within the overall 
workflow (e.g., the patient, clinical team, clinical information systems, labs, pharmacist, genetic 
counselor, and research coordinator).  
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Study Highlights (must be <150 words not including the questions [questions are 30 words] – currently 
149 words) 
What is the current knowledge on the topic? 
Numerous pharmacogenetic clinical guidelines have been published, but the clinical implementation of 
pharmacogenetics has been hindered by many barriers. The Translational Pharmacogenetics Program 
(TPP) of the NIH Pharmacogenomics Research Network facilitated the implementation of 
pharmacogenetic testing in diverse health care settings and examined commonalities and differences in 
institutionally supported pharmacogenetic implementations.  
What question did this study address?  
What lessons can be learned from early pharmacogenetic implementations, and how can they aid other 
institutions?  
What does this study add to our knowledge? 
The TPP collected and normalized numerous pharmacogenetic implementation metrics across seven 
healthcare systems. The pharmacogenetic implementations developed diverse solutions to overcoming 
many barriers. The Clinical Pharmacogenetics Implementation Consortium guidelines created uniformity 
among sites. The TPP also contributed to the establishment of research and informatics infrastructure, 
evaluation of financial issues, and the dissemination of pharmacogenetic education.  
How this might change clinical pharmacology and therapeutics? 
The TPP demonstrated that pharmacogenetics can be implemented across a variety of clinical settings, 
which may facilitate more widespread implementation with the potential to improve clinical outcomes.
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Table 1. Summary of pharmacogenetic implementation metrics across seven TPP sites from 2011 to June 
2015. 
Metrics Findings 
Types of 
Pharmacogenetic 
Implementations 
• Clinical only (n = 2 sites) 
• Research only (n = 3 sites) 
• Clinical and research (n = 2 sites) 
Triggers Prompting 
Pharmacogenetic Test 
Orders* 
• Reactive in select patients (e.g., a relevant drug or procedure is ordered 
for the patient) 
• Preemptive in select patients (e.g., ordered for all patients presenting to a 
select clinical setting regardless of relevant drug use)  
• Preemptive in all patients (e.g., ordered for all patients presenting to the 
healthcare system regardless of relevant drug use) 
• Neither reactive nor preemptive (e.g., if test results were already available 
from a previous test, then they were used to guide therapy) 
Target Patient 
Populations 
• Numerous (e.g., all patients [adults and children], drug-specific, disease-
specific, high-risk ethnic groups [patients of Asian ancestry with an order 
for carbamazepine], etc.)  
Clinical Settings • Numerous (e.g., inpatient and outpatient, cardiac catheterization lab, 
primary care, family medicine, internal medicine, cardiology, 
endocrinology, pediatric and adult gastroenterology, pediatric oncology, 
pediatric HIV, pediatric hematology, neurology, rheumatology, psychiatry, 
etc.) 
Modes of 
Pharmacogenetic Test 
Order Entry 
• Electronic (CPOE; n = 6 sites) 
• Paper (n = 1 site) 
Roles of Ordering 
Providers  
• Physician only (n = 1 site) 
• Research study physician only (n = 2 sites) 
• Physician or nurse practitioner (n = 2 sites) 
• Physician, nurse practitioner, physician assistant, or pharmacist (n = 1 site) 
• Any provider with ordering authority (n = 1 site) 
Options for Ordering 
Pharmacogenetic Test 
Prior to Drug Order* 
• Required  
• Recommended  
Types of Alerts 
Prompting 
Pharmacogenetic Test 
Order or Notification of 
Pharmacogenetic Test 
Results* 
• Active (i.e., alert and/or specific message sent) 
• Passive (i.e., no alert or specific message sent; the test order or test result 
was available on demand) 
• Active + passive 
Persons Receiving 
Results* 
• Provider only 
• Provider + patient 
Total Number of 
Patients Tested 
• 20,258 total across all seven sites (range = 208 - 14,752 by individual sites)  
Percentage of Therapy 
Changes in Response to 
an Actionable Result† 
• Median = 48% (range = 36% - 100%) 
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Genotyping Platforms • Numerous (e.g., Affymetrix DMET™ Plus, Illumina VeraCode® ADME Core 
Panel, Sequenom iPLEX® ADME pharmacogenetic Panel, Life Technologies 
QuantStudio™ 12K Flex, GenMark Dx®, Life Technologies ViiA™ 7, 
polymerase chain reaction with allele-specific primer extension, 
customized arrays, etc.)  
Genotyping Location* • On site 
• Outsourced 
Genotype Call Rates • All sites > 99% 
Estimated Turn-Around-
Time‡ 
• Reactive testing: median = 2.6 days (range = 0.3 - 16 days)  
• Preemptive testing: median = 14 days (range = 1 - 249 days)  
*Number of sites was not included because the counts are specific to each gene-drug pair, which may 
vary within a given site  
†Based on data that was available for CYP2C19-clopidogrel and TPMT-thiopurines from three sites 
‡Time between when pharmacogenetic test was ordered and when the pharmacogenetic test results 
were reported 
CPIC = Clinical Pharmacogenetics Implementation Consortium; CPOE = computerized physician order 
entry; TPP = Translational Pharmacogenetics Program 
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Table 2. Numbers of select pharmacogenetic genes tested for by the TPP sites, along with examples of 
drugs for which actions were taken at some sites, total numbers of pharmacogenetic tests reported to 
EHRs, numbers of actionable genotypes for a select group of commonly implemented gene-drug pairs, 
whether a CPIC guideline is available, and whether there is pharmacogenetic information in the FDA 
label. 
Gene-drug pair 
Number of 
TPP sites 
reporting  
this data 
Numbers of 
distinct test 
results*  
Numbers of 
test results 
reported in 
the EHR† 
Numbers (%) of 
actionable 
results‡  
CPIC 
Guideline FDA Label 
CYP2C19-
clopidogrel 7 57 24,924 7,221 (29.0%)   
TPMT-thiopurines 6 26 20,170 1,987 (9.4%)   
SLCO1B1-
simvastatin 5 30 14,508 3,513 (24.2%)   
CYP2C9/VKORC1-
warfarin 3 30 15,545 5,054 (32.5%)   
CYP2D6-codeine 2 193 2,533 275 (10.8%)   
IFNL3- ribavirin, 
peginterferon 2 3 6,453 4,437 (68.8%)   
DPYD- fluorouracil, 
capecitabine 1 13 2,371 9 (0.4%)   
HLAB-abacavir 1 2 10,816 432 (4.0%)   
 Total 354 97,320 22,928 (23.6%) 8 (100%) 6 (75%) 
*Result formats were gene-specific (e.g., IFNL3 was reported as the genotype for a single variant 
[rs12979860], HLAB was reported as either positive or negative for *57:01, CYP2C9/VKORC1 was 
reported as the compound diplotype, and the results for all other genes were reported as the diplotype 
for the single gene based on multiple genotyped variants)  
†Includes 1,286 no calls and ambiguous calls (1.4%) 
‡Actionable was defined by CPIC guidelines for all gene-drug pairs, except for CYP2C9/VKORC1 where 
actionable was defined by the FDA label when the expected dose did not include the standard 5mg 
starting dose, and the individual sites defined their own actionable CYP2D6-codeine results 
 
CPIC = Clinical Pharmacogenetics Implementation Consortium; CYP2C19 = gene for cytochrome P450 
family 2 subfamily C member 19; CYP2C9 = gene for cytochrome P450 family 2 subfamily C member 9; 
DPYD = gene for dihydropyrimidine dehydrogenase; EHR = EHR; FDA = United States Food & Drug 
Administration; HLA-B = gene for major histocompatibility complex, class I, B; IFNL3 = gene for 
interferon, lambda 3, also known as interleukin 28B; SLCO1B1 = gene for solute carrier organic anion 
transporter family member 1B1; TPMT = gene for thiopurine S-methyltransferase; VKORC1 = gene for 
vitamin K epoxide reductase complex subunit 1. 
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Table 3. Pharmacogenomic guidelines and implementations at TPP sites.  
Gene-Drug Interaction 
Number of 
Implementing 
Sites 
CYP2C19-clopidogrel 7 
TPMT-thiopurines 6 
CYP2C9/VKORC1-warfarin 4 
SLCO1B1-simvastatin 5 
CYP2D6/CYP2C19-TCAs 2 
CYP2D6-codeine 2 
HLA-B-abacavir 2 
CYP2D6-SSRIs 1 
CYP3A5-tacrolimus 1 
IFNL3-ribavirin/interferon 1 
ITPA-ribavirin 1 
GLCC1-budesonide,fluticasone, triamcinolone 1 
CYP3A4-amlodipine, atorvastatin, simvastatin, and lovastatin 1 
HLA-B-allopurinol 0 
HLA-B-carbamazepine 1 
DPYD-5FU/capecitabine 1 
IL28B-pegInteron 2 
HLA-B-phenytoin, fosphenytoin therapy 1 
G6PD-rasburicase, Septra 1 
CFTR-Ivacaftor 0 
UGT1A1-irinotecan 2 
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Text in bold indicates that CPIC guidelines have been published for the gene-
drug(s) interaction.  TCAs – tricyclic antidepressants.  SSRIs - selective serotonin 
re-uptake inhibitors. 
 
 
 
 
 
 
CYP2D6 - tamoxifen 1 
5-HTT-SSRIs 1 
DRD4-methylphenidate 1 
HTR 2A/2C-clozapine, aripiprazole 1 
NAT2-Isoniazid 1 
OPRM1-Naltrexone 1 
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